Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

Launched by MAYO CLINIC · Apr 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether artificial intelligence (AI) can help detect endometrial cancer or its early warning signs in women who have experienced post-menopausal bleeding (PMB). The researchers are using transvaginal ultrasound, a type of imaging test that involves a small probe inserted into the vagina, to see if AI can analyze the pictures and identify potential issues early on. This study is currently looking for female participants aged 55 and older who have had at least one episode of PMB and have an endometrial biopsy available from specific healthcare centers.

If you decide to participate, you will undergo a transvaginal ultrasound, and the AI will analyze the images taken during the test. This could help in understanding your condition better and possibly lead to earlier diagnosis and treatment if necessary. To join the study, you need to be willing to participate and meet the criteria, but you cannot have had certain diagnostic tests done more than 90 days apart or have any physical issues that would prevent you from having the ultrasound. Your involvement could play a vital role in improving how we screen for endometrial cancer in the future!

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 55 years
• • At least one episode of postmenopausal bleeding (PMB)
• • Endometrial biopsy available from at Mayo Clinic (MN, AZ, FL), Mayo Clinic Health System (MCHS), or an external institution
• • Acceptance to participate in the study
• Exclusion Criteria:
• • Diagnostic tests performed more than 90 days apart
• • Physical impediment/refusal to undergo transvaginal ultrasound (TVUS)